These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18774413)

  • 21. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
    AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-HIV agents. Controversial findings on abacavir and heart attacks.
    TreatmentUpdate; 2008 Mar; 20(2):1-5. PubMed ID: 18661643
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir update.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 28. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.
    De Pablo C; Orden S; Apostolova N; Blanquer A; Esplugues JV; Alvarez A
    AIDS; 2010 Jun; 24(9):1259-66. PubMed ID: 20453628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of HIV disease in 1993/1994.
    Fischl MA
    AIDS Clin Rev; 1993-1994; ():167-87. PubMed ID: 8217898
    [No Abstract]   [Full Text] [Related]  

  • 31. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].
    Walter M
    MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084
    [No Abstract]   [Full Text] [Related]  

  • 32. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®).
    Dellamonica P; Katlama C; Lévy-Bachelot L; Daures JP; Finkielsztejn L
    Med Mal Infect; 2013 Dec; 43(11-12):467-74. PubMed ID: 24262915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
    Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
    Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abacavir at last.
    Gilden D
    GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA reviewing safety of Ziagen and Videx.
    AIDS Read; 2008 May; 18(5):236. PubMed ID: 18589877
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.